At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Apremilastdrug
Likely dose
Apremilast 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-label Multi-center Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Apremilast in Subjects With Recalcitrant Plaque-type Psoriasis
In Brief
A Phase 2 clinical trial evaluating Apremilast for Psoriasis-Type Psoriasis and Plaque-Type Psoriasis. Completed, enrolled 31 participants across 4 sites.
Detailed Summary
The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis-Type Psoriasis, Plaque-Type Psoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedAug 2007
Primary CompletionApr 2009
Study CompletionMay 2009
TodayJul 2026
First PostedAug 27, 2007
Enrollment StartAug 1, 2007
Primary CompletionApr 1, 2009
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.8 years ago
Interventions
Apremilastdrug
20 mg PO (by mouth) twice per day (BID) for 84 days and then an additional 84 days during the optional treatment extension period. For subjects meeting the dose escalation criteria, dosage during the optional treatment extension period can be increased to 30 mg BID.